BioSpace News Archive

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”) today reported its financial results for the full year ended December 31, 2023 and outlined recent corporate and clinical development highlights.

Scientific Industries, Inc. announced it filed a Form 10K on March 29, 2024, for its full year financial results ended December 31, 2023, and issued a press release reporting its full year 2023 before the market open on April 1, 2024.

Zentalis® Pharmaceuticals, Inc. announced that on April 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 105,950 shares of the Company’s common stock to four newly hired employees.

LENSAR, Inc. announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company’s common stock.

Acorda Therapeutics, Inc. announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.

FSD Pharma Inc. announced that the Company filed its audited annual financial results for the fourth quarter and full year ended December 31, 2023 and accompanying management’s discussion and analysis on Thursday March 28, 2024 and today filed its Annual Report on 20-F for the year ended December 31, 2023.

Gritstone bio, Inc. announced the pricing of an approximately $32.5 million underwritten public offering of its common stock and accompanying common warrants to purchase common stock, before deducting underwriting discounts and commissions and offering expenses.

MedMira Inc., reported on its financial results for the quarter ended January 31, 2024.

ADC Therapeutics SA announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security and infectious disease, announced that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc.